Home > Publications database > Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group. > print

001     120096
005     20240228135011.0
024 7 _ |a 10.1007/s00401-013-1213-7
|2 doi
024 7 _ |a pmid:24264598
|2 pmid
024 7 _ |a pmc:PMC3895219
|2 pmc
024 7 _ |a 0001-6322
|2 ISSN
024 7 _ |a 1432-0533
|2 ISSN
024 7 _ |a altmetric:1932063
|2 altmetric
037 _ _ |a DKFZ-2017-00683
041 _ _ |a eng
082 _ _ |a 610
100 1 _ |a Gottardo, Nicholas G
|b 0
245 _ _ |a Medulloblastoma Down Under 2013: a report from the third annual meeting of the International Medulloblastoma Working Group.
260 _ _ |a Berlin
|c 2014
|b Springer
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1490793518_22980
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Medulloblastoma is curable in approximately 70% of patients. Over the past decade, progress in improving survival using conventional therapies has stalled, resulting in reduced quality of life due to treatment-related side effects, which are a major concern in survivors. The vast amount of genomic and molecular data generated over the last 5-10 years encourages optimism that improved risk stratification and new molecular targets will improve outcomes. It is now clear that medulloblastoma is not a single-disease entity, but instead consists of at least four distinct molecular subgroups: WNT/Wingless, Sonic Hedgehog, Group 3, and Group 4. The Medulloblastoma Down Under 2013 meeting, which convened at Bunker Bay, Australia, brought together 50 leading clinicians and scientists. The 2-day agenda included focused sessions on pathology and molecular stratification, genomics and mouse models, high-throughput drug screening, and clinical trial design. The meeting established a global action plan to translate novel biologic insights and drug targeting into treatment regimens to improve outcomes. A consensus was reached in several key areas, with the most important being that a novel classification scheme for medulloblastoma based on the four molecular subgroups, as well as histopathologic features, should be presented for consideration in the upcoming fifth edition of the World Health Organization's classification of tumours of the central nervous system. Three other notable areas of agreement were as follows: (1) to establish a central repository of annotated mouse models that are readily accessible and freely available to the international research community; (2) to institute common eligibility criteria between the Children's Oncology Group and the International Society of Paediatric Oncology Europe and initiate joint or parallel clinical trials; (3) to share preliminary high-throughput screening data across discovery labs to hasten the development of novel therapeutics. Medulloblastoma Down Under 2013 was an effective forum for meaningful discussion, which resulted in enhancing international collaborative clinical and translational research of this rare disease. This template could be applied to other fields to devise global action plans addressing all aspects of a disease, from improved disease classification, treatment stratification, and drug targeting to superior treatment regimens to be assessed in cooperative international clinical trials.
536 _ _ |a 312 - Functional and structural genomics (POF3-312)
|0 G:(DE-HGF)POF3-312
|c POF3-312
|f POF III
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed,
650 _ 7 |a Antineoplastic Agents
|2 NLM Chemicals
700 1 _ |a Hansford, Jordan R
|b 1
700 1 _ |a McGlade, Jacqueline P
|b 2
700 1 _ |a Alvaro, Frank
|b 3
700 1 _ |a Ashley, David M
|b 4
700 1 _ |a Bailey, Simon
|b 5
700 1 _ |a Baker, David L
|b 6
700 1 _ |a Bourdeaut, Franck
|b 7
700 1 _ |a Cho, Yoon-Jae
|b 8
700 1 _ |a Clay, Moira
|b 9
700 1 _ |a Clifford, Steven C
|b 10
700 1 _ |a Cohn, Richard J
|b 11
700 1 _ |a Cole, Catherine H
|b 12
700 1 _ |a Dallas, Peter B
|b 13
700 1 _ |a Downie, Peter
|b 14
700 1 _ |a Doz, François
|b 15
700 1 _ |a Ellison, David W
|b 16
700 1 _ |a Endersby, Raelene
|b 17
700 1 _ |a Fisher, Paul G
|b 18
700 1 _ |a Hassall, Timothy
|b 19
700 1 _ |a Heath, John A
|b 20
700 1 _ |a Hii, Hilary L
|b 21
700 1 _ |a Jones, David
|0 P:(DE-He78)551bb92841f634070997aa168d818492
|b 22
|u dkfz
700 1 _ |a Junckerstorff, Reimar
|b 23
700 1 _ |a Kellie, Stewart
|b 24
700 1 _ |a Kool, Marcel
|0 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
|b 25
|u dkfz
700 1 _ |a Kotecha, Rishi S
|b 26
700 1 _ |a Lichter, Peter
|0 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
|b 27
|u dkfz
700 1 _ |a Laughton, Stephen J
|b 28
700 1 _ |a Lee, Sharon
|b 29
700 1 _ |a McCowage, Geoff
|b 30
700 1 _ |a Northcott, Paul A
|0 P:(DE-HGF)0
|b 31
700 1 _ |a Olson, James M
|b 32
700 1 _ |a Packer, Roger J
|b 33
700 1 _ |a Pfister, Stefan
|0 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
|b 34
|u dkfz
700 1 _ |a Pietsch, Torsten
|b 35
700 1 _ |a Pizer, Barry
|b 36
700 1 _ |a Pomeroy, Scott L
|b 37
700 1 _ |a Remke, Marc
|b 38
700 1 _ |a Robinson, Giles W
|b 39
700 1 _ |a Rutkowski, Stefan
|b 40
700 1 _ |a Schoep, Tobias
|b 41
700 1 _ |a Shelat, Anang A
|b 42
700 1 _ |a Stewart, Clinton F
|b 43
700 1 _ |a Sullivan, Michael
|b 44
700 1 _ |a Taylor, Michael D
|b 45
700 1 _ |a Wainwright, Brandon
|b 46
700 1 _ |a Walwyn, Thomas
|b 47
700 1 _ |a Weiss, William A
|b 48
700 1 _ |a Williamson, Dan
|b 49
700 1 _ |a Gajjar, Amar
|b 50
773 _ _ |a 10.1007/s00401-013-1213-7
|g Vol. 127, no. 2, p. 189 - 201
|0 PERI:(DE-600)1458410-4
|n 2
|p 189 - 201
|t Acta neuropathologica
|v 127
|y 2014
|x 1432-0533
909 C O |o oai:inrepo02.dkfz.de:120096
|p VDB
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 22
|6 P:(DE-He78)551bb92841f634070997aa168d818492
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 25
|6 P:(DE-He78)4c28e2aade5f44d8eca9dd8e97638ec8
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 27
|6 P:(DE-He78)e13b4363c5fe858044ef8a39c02c870c
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 31
|6 P:(DE-HGF)0
910 1 _ |a Deutsches Krebsforschungszentrum
|0 I:(DE-588b)2036810-0
|k DKFZ
|b 34
|6 P:(DE-He78)f746aa965c4e1af518b016de3aaff5d9
913 1 _ |a DE-HGF
|l Krebsforschung
|1 G:(DE-HGF)POF3-310
|0 G:(DE-HGF)POF3-312
|2 G:(DE-HGF)POF3-300
|v Functional and structural genomics
|x 0
|4 G:(DE-HGF)POF
|3 G:(DE-HGF)POF3
|b Gesundheit
914 1 _ |y 2014
915 _ _ |a Nationallizenz
|0 StatID:(DE-HGF)0420
|2 StatID
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b ACTA NEUROPATHOL : 2015
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0310
|2 StatID
|b NCBI Molecular Biology Database
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Thomson Reuters Master Journal List
915 _ _ |a WoS
|0 StatID:(DE-HGF)0110
|2 StatID
|b Science Citation Index
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
915 _ _ |a WoS
|0 StatID:(DE-HGF)0111
|2 StatID
|b Science Citation Index Expanded
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1030
|2 StatID
|b Current Contents - Life Sciences
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1050
|2 StatID
|b BIOSIS Previews
915 _ _ |a IF >= 10
|0 StatID:(DE-HGF)9910
|2 StatID
|b ACTA NEUROPATHOL : 2015
920 1 _ |0 I:(DE-He78)B062-20160331
|k B062
|l Pädiatrische Neuroonkologie
|x 0
920 1 _ |0 I:(DE-He78)B060-20160331
|k B060
|l Molekulare Genetik
|x 1
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-He78)B062-20160331
980 _ _ |a I:(DE-He78)B060-20160331
980 _ _ |a UNRESTRICTED

LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21